Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: bevacizumab|DRUG: Carboplatin|DRUG: ABI-007
Sponsor: Loyola University
Collaborators: Genentech, Inc.|Celgene Corporation